Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2024 14:02 ET | Source: 7 Hills Pharma

7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors

7 Hills safely doses first cancer patient with alintegimod, a novel selective integrin activator designed to improve the efficacy of checkpoint blockade.
June 03, 2024 12:57 ET | Source: 7 Hills Pharma

7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic

Houston biotech awarded $4.7MM in homegrown Texas support for new technology to safely improve the treatment of advanced blood cancers and genetic diseases
March 08, 2022 17:32 ET | Source: 7 Hills Pharma

7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma

HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-class oral small...
November 01, 2021 15:08 ET | Source: 7 Hills Pharma

7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines

HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-concept oral small...
November 09, 2020 05:30 ET | Source: 7 Hills Pharma

7 Hills Pharma Announces First Healthy Volunteers Dosed in Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines

HOUSTON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases,...
July 24, 2018 08:00 ET | Source: 7 Hills Pharma

7 Hills Pharma Appoints Lionel D. Lewis as Chief Medical Officer

HOUSTON, July 24, 2018 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a privately-held immunotherapy company focused on development of novel tumor-targeting cell adhesion agents, today announced the...
June 26, 2018 08:00 ET | Source: 7 Hills Pharma

7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program

HOUSTON, June 26, 2018 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a privately-held immunotherapy company focused on development of novel tumor-targeting cell adhesion agents, announced today the formation...